SL Therapeutics, Inc. engages in cell therapy and medical device businesses. The company develops cell therapeutic solutions based on its cell reprogramming technology to treat various diseases with a focus on spinal cord injury, and age and genetically related diseases; and hair follicle cells, skin cells, and cells of the central nervous system. It also manufactures automated magnetic resonance imaging systems; and Supra Elite and Dexino bone mineral density measurement devices. The company was formerly known as StemLab Inc. SL Therapeutics, Inc. was founded in 2011 and is headquartered in Seoul, South Korea.
Metrics to compare | 258540 | Peers Peers - average of corresponding metrics from companies closely matching 258540: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship258540PeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.3x | |
Upside (Analyst Target) | 0.0% | 0.0% | 40.1% | |
Fair Value Upside | Unlock | 0.0% | 5.1% | Unlock |